Kurzfassung

Mylight CSOK583A12301 A 52-week mulicenter, randomized, double-masked, 2-arm parallel study to compare efficacy, safety and immunogenicity of SOK583A1 to Eylea, administered intravitreally, in patients with neovascular age-relate macular degeneration